Study Phase 3

An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)

Trial Information

Generic NameTrabectedinProduct NameYONDELIS®Therapeutic AreaAntineoplastic and Immunomodulating AgentsProduct ClassAntineoplastic AgentsPharmacological SubgroupPlant Alkaloids and Other Natural ProductsChemical SubgroupOther Plant Alkaloids and Natural ProductsCondition StudiedSarcoma
Sponsor Protocol NumberET-C-002-07Enrollment121Data PartnerJohnson & Johnson% Female38.8%Mean/Median Age (Years)48% White88.4%

Supporting Documentation

  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available
Additional Information

Please note: individual participant-level data are not available for this trial. Only the protocol, statistical analysis plan, and full clinical study report are available.

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.